This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy
by Zacks Equity Research
Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
by Zacks Equity Research
Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.
bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.
Gilead's (GILD) Breast Cancer Drug MAA Validated by EMA
by Zacks Equity Research
Gilead's (GILD) regulatory application for breast cancer drug has been validated by the regulatory body in Europe.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $65.23 in the latest trading session, marking a +1.94% move from the prior day.
The Zacks Analyst Blog Highlights: UnitedHealth Group, Sony, American Tower, Advanced Micro Devices and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth Group, Sony, American Tower, Advanced Micro Devices and Gilead Sciences
Top Stock Reports for UnitedHealth, Sony & American Tower
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Sony (SNE), and American Tower (AMT).
Roche (RHHBY) Stops Dosing in Huntington's Disease Study
by Zacks Equity Research
Roche (RHHBY) halts dosing in the phase III GENERATION HD1 study evaluating tominersen in manifest Huntington's disease following recommendation from an iDMC.
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk
by Zacks Equity Research
Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.
Gilead Sciences (GILD) Stock Moves -0.53%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.08 in the latest trading session, marking a -0.53% move from the prior day.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments
by Zacks Equity Research
Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.
Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails
by Zacks Equity Research
Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.75 in the latest trading session, marking a +0.2% move from the prior day.
Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL
by Zacks Equity Research
Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.
Why Is Gilead (GILD) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.
FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses
by Zacks Equity Research
FATE reports a wider Q4 loss on increased R&D expenses.